Clinical trials: Chronic End Stage Renal Failure
End Stage Renal Disease
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
The purpose of this study is to compare the immune response to HEPLISAV™ booster injection with the immune response to Engerix-B® and Fendrix® booster vaccinations among patients with end stage renal disease (ESRD) on…
- Trial name
- NCT01195246
- Testing
- HEPLISAV, Engerix-B, Fendrix
- Where
- 19 sites in Germany
- Volunteers
- 155 people
- Sponsor
- Dynavax Technologies Corporation
Anemia of End Stage Renal Disease
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
The purpose of this study is to prospectively collect data on doses of Erythropoietic Stimulating Agents (ESA) and Intravenous Iron, and the markers of erythropoietic activity and iron status.
- Trial name
- NCT01719146
- Testing
- Specimen collection
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- University of Louisville
End Stage Renal Disease
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus.
- Trial name
- NCT03321656
- Testing
- Tacrolimus, Envarsus XR
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Roberto Gedaly
Chronic Kidney Disease
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
- Trial name
- NCT01071070
- Testing
- paricalcitol
- Where
- 12 sites in China
- Volunteers
- 216 people
- Sponsor
- Abbott
Renal Failure
Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Primary Objective: To determine the absolute bioavailability of furosemide 500 mg (Lasix® Special) oral formulation in patients with chronic renal failure undergoing peritoneal dialysis.
- Trial name
- NCT01724788
- Testing
- FUROSEMIDE, FUROSEMIDE (HOE058)
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Sanofi
End-stage Renal Disease, Hemodialysis
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
High-efficiency post-dilution online hemodiafiltration (OL-HDF) using high-flux dialyzer and requiring high blood flow rate (BF ≥400 mL/min) has been reported to enhance protein-bound toxin and middle molecular toxin removal and…
- Trial name
- NCT03288922
- Testing
- Limited BF OL-HDF with SHF, High-efficiency OL-HDF
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Chulalongkorn University
End-stage Renal Disease
Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration
An increase of the free fraction may allow a better removal of of protein-bound uremic toxins during dialysis. During predilution hemodiafiltration, the sodium chloride (NaCl) concentration will be increased in the infusion fluid…
- Trial name
- NCT01923961
- Testing
- HDF NaCl, Hemodialysis, Standard Predilution Hemodiafiltration
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- EXcorLab GmbH
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01901107
- Testing
- Kiklin capsules
- Where
- 8 sites in Japan
- Volunteers
- 1,078 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
Impact of Vitamin D Therapies on Chronic Kidney Disease
This investigation will consist of a prospective study utilizing two separate populations of patients with 25(OH)D deficiency, one population with chronic kidney disease (CKD) and one with normal renal function.
- Trial name
- NCT01222234
- Testing
- Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Kansas Medical Center
Hyperparathyroidism, Arterial Stiffness
Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism
Active parathyroid glands among renal dialysis patients contribute to calcified and hardened blood vessels. Such damage to the blood vessels, in turn, takes a significant toll in terms of cardiovascular disease.
- Trial name
- NCT01143987
- Testing
- Cinacalcet
- Where
- Hong Kong
- Volunteers
- 44 people
- Sponsor
- Chinese University of Hong Kong
Hypoalbuminemia, Protein-energy Malnutrition
Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
Study of efficiency and safety of oral nutritional supplements with anti-inflammatory and antioxidative properties combined with an appetite stimulant with anti-inflammatory properties (pentoxiphylline) in treatment of…
- Conditions
- Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress
- Trial name
- AIONID (NCT00561093)
- Testing
- pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa)
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
End Stage Renal Disease (ESRD)
The Effect of Gum Arabic (GA) on Residual Renal Function in Adult Dialysis Patients in Abu Dhabi
Gum Arabic (GA), derived from Acacia trees, has shown potential benefits in metabolic, renal, and inflammatory conditions. This study explores the impact of GA on residual renal function in end-stage renal disease (ESRD) patients…
- Trial name
- GAESRD (NCT06836206)
- Testing
- Gum Arabic, Water
- Where
- United Arab Emirates
- Volunteers
- 40 people
- Sponsor
- Abu Dhabi Health Services Company
Chronic Renal Failure
Dose-finding of Rivaroxaban in Hemodialysis
Rivaroxaban is a recently developed factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disease. There are no data on dose adjustments in patients with severe chronic renal failure.
- Trial name
- NCT02047006
- Testing
- Rivaroxaban 10 mg
- Where
- 2 sites in Belgium
- Volunteers
- 18 people
- Sponsor
- AZ Sint-Jan AV
Chronic Kidney Diseases
Medico-economic Evaluation of a Telemedicine System for the Management of Chronic Renal Failure
The main objective of this study is to demonstrate the efficiency ( cost-effectiveness ) of a telemedicine system : eNephro Application , compared with traditional care in the management of chronic renal failure in different…
- Trial name
- eNephro (NCT02082093)
- Testing
- Telemedicine System
- Where
- 8 sites in France
- Volunteers
- 635 people
- Sponsor
- Pharmagest Interactive
End Stage Renal Disease, Hypertension, Renal
Efficacy of L-methylfolate and Methylcobalamine in Treating Resistant Hypertension Associated With Elevated Serum Homocysteine in Hemodialysis Patients.
The aim of the study is to evaluate the efficacy of L-methylfolate in combination with methylcobalamine in reducing homocysteine blood levels in hypertensive end-stage renal disease patients on regular hemodialysis and its…
- Trial name
- NCT05807711
- Testing
- L-Methyl Folate and methylcobalamine
- Where
- Egypt
- Volunteers
- 51 people
- Sponsor
- Alexandria University
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
End-Stage Renal Disease, Type 2 Diabetes Mellitus
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis
This study is a multi-center, double-blinded, randomized, study of bardoxolone methyl treatment in patients with End-Stage Renal Disease (ERSD) and Type 2 Diabetes Mellitus (T2DM) on peritoneal dialysis.
- Trial name
- NCT01576887
- Testing
- Bardoxolone Methyl 20 mg
- Sponsor
- Biogen
Pure Red-cell Aplasia
A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
The purpose of this study is to collect historical occurrences of risk factors that are potentially associated with the development of anti-erythropoietin (EPO) antibody positive pure red cell aplasia (PRCA) in participants with…
- Trial name
- NCT00211068
- Testing
- No intervention
- Where
- 22 sites in Brazil, France and 5 more
- Volunteers
- 124 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Volunteers
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.
- Trial name
- NCT02327546
- Testing
- AKB-6548, Ferrous Sulfate
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
End-stage Renal Disease
The Benefit of Hemodialysis Plus Hemoperfusion on Mortality
This multi-center, open-label, randomized controlled trial aims to investigate the efficacy of hemoperfusion (HP) combined with hemodialysis (HD) by evaluating all-cause mortality and cardiovascular mortality in maintenance…
- Trial name
- NCT03227770
- Testing
- hemoperfusion combined with hemodialysis, hemodialysis
- Where
- 11 sites in China
- Volunteers
- 1,362 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.